Results 141 to 150 of about 3,396,679 (311)

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

Molecular Oncology, EarlyView.
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert, Lauren van den Broecke, Osman Aksoy, Judith Lind, Sonia Vallet, Arne Van der Vreken, Gamze Ates, Ann Massie, Ken Maes, Kim De Veirman, Elke De Bruyne, Karin Vanderkerken, Klaus Podar, Eline Menu   +13 more
wiley   +1 more source

Survival of Patients with Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Study

, 2014
Nelli Bejanyan, Daniel J. Weisdorf, Brent R. Logan, Hai-Lin Wang, Steven M. Devine, Marcos de Lima, Donald Bunjes, Mei-Jie Zhang   +7 more
openalex   +1 more source

Oral squamous cell carcinoma involving the maxillae: Factors affecting local recurrence and the value of salvage treatment for overall survival [PDF]

, 2020
Fons Joeri Bernard Slieker, Remco de Bree, Ellen M. Van Cann   +2 more
openalex   +1 more source

Effect of pleural invasion on survival of patients with small cell lung cancer: Propensity score analysis and nomogram establishment based on the SEER database [PDF]

, 2023
Jie Yang, Hui Yin, Mingshan Liu, Guowen Zou, Bentong Yu   +4 more
openalex   +1 more source

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

Molecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser, Jan Niklas Schäfer, Shraga Nahum Goldberg, Philipp Maximilian Kazmierczak, Moritz Nikolaus Gröper, Philipp Franz Linden, Elif Öcal, Tanja Burkard, Stefanie Corradini, Najib Ben Khaled, Moritz Wildgruber, Max Seidensticker, Jens Ricke, Matthias Stechele, Marianna Alunni‐Fabbroni   +14 more
wiley   +1 more source

The Cytotoxic Effect of Metformin on Cervical Cancer (Hela) Cells in Comparison with Non-Cancerous Kidney Cells

Majallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Qum, 2018
Background and Objectives: Studies have shown that antidiabetic drugs can inhibit cancer cells proliferation. The aim of this study was to investigate the cytotoxic effects of metformin on cervical cancer (Hela) cells in comparison with non-cancerous ...
Zahra Gholamhoseyni, Rahim Ahmadi, Yeganeh Hamidi   +2 more
doaj  

MP19-10 PROGNOSTIC SIGNIFICANCE OF C-REACTIVE PROTEIN ON SURVIVAL IN PATIENTS WITH NON-METASTATIC PAPILLARY RENAL CELL CARCINOMA: AN INTERNATIONAL MULTI-RACIAL STUDY [PDF]

, 2019
Masahiro Toide, Kazutaka Saito, Yosuke Yasuda, Kenji Tanabe, Shohei Fukuda, Hiroshi Fukushima, Minato Yokoyama, Junichiro Ishioka, Yoh Matsuoka, Dattataya Patil, Brittney Cotta, Sunil Patel, Viraj A. Master, Ithaar Derweesh, Yasuhisa Fujii   +14 more
openalex   +1 more source

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

Molecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, Avanti Gupte, Jenna Thibodeau, Shuang Liu, Jinli Yang, Guan Wang, Holly Edwards, Lisa A. Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Julie Boerner, Maik Hüttemann, Jay Yang, Yue Wang, Jeffrey W. Taub, Yubin Ge   +18 more
wiley   +1 more source

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

Molecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak, Bodee Nutho, Worawat Wattanathana, Narumon Phaonakrop, Bunnatut Panasawatwong, Katharina Erlenbach‐Wuensch, Sittiruk Roytrakul, Regine Schneider‐Stock, Pithi Chanvorachote   +8 more
wiley   +1 more source

Editorial: Molecular Mechanisms of Selective Autophagy in Human Disease

Frontiers in Cell and Developmental Biology, 2020
Valentina Cianfanelli, Paolo Grumati, Francesca Nazio   +2 more
doaj   +1 more source